Sparks commentary - Immix Biopharma

Healthcare

Sparks - Immix Biopharma

More on this equity
Scientist using protective robber gloves for handling substances and experiments
Immix Biopharma (NASDAQ: IMMX) – Accelerated NEXICART-2 progress
Published by Arron Aatkar, PhD

Immix Biopharma has announced the accelerated progress of the NEXICART-2 trial, which now has 18 active clinical trial sites (compared to 14 in the prior update, in May 2025). The NEXICART-2 trial is a US-based, open-label, single-arm, multi-site, dose-escalation/expansion Phase I/II trial. It is evaluating lead CAR-T therapy, NXC-201, as a potential treatment for patients with relapsed/refractory amyloid light chain amyloidosis (r/r ALA). Management has communicated that it is on track to submit a biologics license application once 40 r/r ALA patients have been treated (guided for mid-2026).

The latest clinical data readout was presented at ASCO 2025, corresponding to the first 10 patients treated in the trial. A complete response rate of 70% was reported, which was considered favourable, according to key opinion leaders (KOLs) in the corresponding KOL event.

 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free